JP5405829B2 - トロンボモジュリン変異体を用いた急性障害の治療方法 - Google Patents

トロンボモジュリン変異体を用いた急性障害の治療方法 Download PDF

Info

Publication number
JP5405829B2
JP5405829B2 JP2008535706A JP2008535706A JP5405829B2 JP 5405829 B2 JP5405829 B2 JP 5405829B2 JP 2008535706 A JP2008535706 A JP 2008535706A JP 2008535706 A JP2008535706 A JP 2008535706A JP 5405829 B2 JP5405829 B2 JP 5405829B2
Authority
JP
Japan
Prior art keywords
thrombomodulin
stm
renal failure
acute
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008535706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511597A5 (enExample
JP2009511597A (ja
Inventor
ブライアン・ウィリアム・グリンネル
サーマン・ドワイト・マッキンニー
ブルース・エイ・モリトリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2009511597A publication Critical patent/JP2009511597A/ja
Publication of JP2009511597A5 publication Critical patent/JP2009511597A5/ja
Application granted granted Critical
Publication of JP5405829B2 publication Critical patent/JP5405829B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008535706A 2005-10-13 2006-10-12 トロンボモジュリン変異体を用いた急性障害の治療方法 Expired - Fee Related JP5405829B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72637605P 2005-10-13 2005-10-13
US60/726,376 2005-10-13
PCT/US2006/040069 WO2007047430A2 (en) 2005-10-13 2006-10-12 Method of treating acute failure with thrombomodulin variant

Publications (3)

Publication Number Publication Date
JP2009511597A JP2009511597A (ja) 2009-03-19
JP2009511597A5 JP2009511597A5 (enExample) 2009-11-12
JP5405829B2 true JP5405829B2 (ja) 2014-02-05

Family

ID=37670944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008535706A Expired - Fee Related JP5405829B2 (ja) 2005-10-13 2006-10-12 トロンボモジュリン変異体を用いた急性障害の治療方法

Country Status (13)

Country Link
US (1) US20080255047A1 (enExample)
EP (1) EP1948216B1 (enExample)
JP (1) JP5405829B2 (enExample)
AT (1) ATE503489T1 (enExample)
CA (1) CA2625888C (enExample)
CY (1) CY1112438T1 (enExample)
DE (1) DE602006021048D1 (enExample)
DK (1) DK1948216T3 (enExample)
ES (1) ES2360610T3 (enExample)
PL (1) PL1948216T3 (enExample)
PT (1) PT1948216E (enExample)
SI (1) SI1948216T1 (enExample)
WO (1) WO2007047430A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076298B2 (en) 2006-12-12 2011-12-13 Eli Lilly And Company Treating acute renal failure with soluble thrombomodulin variants
BRPI0922033A2 (pt) * 2008-11-12 2015-12-15 Lilly Co Eli composições e métodos de uso de variantes de trombomodulina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2022713A1 (en) * 1989-08-11 1991-02-12 Nils U. Bang Human thrombomodulin derivatives
CA2129370A1 (en) * 1992-02-05 1993-08-19 David Richard Light Protease-resistant thrombomodulin analogs
ATE249234T1 (de) * 1993-12-17 2003-09-15 Mochida Pharm Co Ltd Lösliches thrombomodulin enthaltende zubereitung
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors

Also Published As

Publication number Publication date
EP1948216A2 (en) 2008-07-30
CA2625888C (en) 2015-09-22
WO2007047430A3 (en) 2007-05-24
ATE503489T1 (de) 2011-04-15
WO2007047430A2 (en) 2007-04-26
DE602006021048D1 (de) 2011-05-12
CA2625888A1 (en) 2007-04-26
WO2007047430A8 (en) 2008-04-10
EP1948216B1 (en) 2011-03-30
PL1948216T3 (pl) 2011-10-31
JP2009511597A (ja) 2009-03-19
ES2360610T3 (es) 2011-06-07
CY1112438T1 (el) 2015-12-09
DK1948216T3 (da) 2011-06-06
PT1948216E (pt) 2011-05-06
US20080255047A1 (en) 2008-10-16
SI1948216T1 (sl) 2011-07-29

Similar Documents

Publication Publication Date Title
Sharfuddin et al. Soluble thrombomodulin protects ischemic kidneys
Sukhatme Vascular access stenosis: Prospects for prevention and therapy
AU2009322865B2 (en) Polypeptide for treating or preventing adhesions
RU2770698C2 (ru) Способы лечения кальцификации тканей
JP2008263991A (ja) 修飾されたアネキシン蛋白質および血栓症を防ぐための方法
US20020165160A1 (en) Angiogenically effective unit dose of FGF and method of administering
Kassimatis et al. Ex vivo delivery of Mirococept: A dose-finding study in pig kidney after showing a low dose is insufficient to reduce delayed graft function in human kidney
JP2012254992A (ja) 修飾アネキシンタンパク質および血栓症を防止するための方法
Cagliani et al. Anti–interferon-α receptor 1 antibodies attenuate inflammation and organ injury following hemorrhagic shock
CN114699430A (zh) 线粒体及其在胰腺炎中的应用和应用方法
JP5272228B2 (ja) 可溶性トロンボモジュリン変異体を用いる急性腎不全の治療
JP2009511597A (ja) トロンボモジュリン変異体を用いた急性障害の治療方法
Ishikawa et al. Milk fat globule-epidermal growth factor-VIII–derived oligopeptide 3 (MOP3) attenuates inflammation and improves survival in hepatic ischemia/reperfusion injury
Waerhaug et al. Recombinant human activated protein C attenuates endotoxin-induced lung injury in awake sheep
WO2019040085A1 (en) PERFUSION COMPOSITIONS AND METHODS OF USING EX VIVO ORGAN PERFUSION ALPHA -1 ANTI-TRYPSIN
CA2623518C (en) Method for treating or preventing ischemia reperfusion injury or multi-organ failure
JP2008007512A (ja) 動脈狭窄の減弱方法
Ege et al. Importance of pulmonary artery perfusion in cardiac surgery
US20220372169A1 (en) Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
CN108355133A (zh) 靶向cxcr7的药物组合物和方法
US20230272058A1 (en) Compositions and methods for preventing acute kidney injury-induced acute lung injury (aki-ali)
Ishikawa et al. MFG-E8-derived oligopeptide 3 (MOP3) attenuates inflammation and improves survival in hepatic ischemia/reperfusion injury
CN118369351A (zh) Dsg2组合物和方法
KR20210060574A (ko) 응고 이상을 수반하는 패혈증의 치료 및/또는 개선을 위한 의약
CRANSTON In the rabbit, the production of pyrogen from leucocytes appears to be a two-stage process. There is an initial" activation" step, which involves

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130612

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees